Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma

Sanjay P. Bagaria, Partha S. Ray, Richard W Joseph, Michael G. Heckman, Bhupendra Rawal, Richard J. Gray, Barbara A Pockaj, Nabil Wasif

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

BACKGROUND: Lymph lymph node metastasis from melanoma ≤0.50 mm (ultrathin) is an infrequent event. However, because many newly diagnosed melanomas are ultrathin, a significant proportion of patients who present with lymph node disease have an ultrathin melanoma. The authors hypothesized that ultrathin melanomas that present with lymph node metastasis represent biologically aggressive lesions with a worse prognosis. METHODS: The Surveillance, Epidemiology, and End Results registry data were queried to identify patients with cutaneous melanoma who presented with lymph node metastasis diagnosed between 1998 and 2008. Hazard ratios (HRs) from Cox proportional hazards regression models were used to compare disease-specific survival (DSS) between various tumor depths. RESULTS: In total, 6134 patients with lymph node-positive melanoma were identified and stratified according to tumor depth, including 588 (10%) with a tumor depth ≤0.50 mm, 519 (8%) with a tumor depth from 0.51 to 1.00 mm, 1669 (27%) with a tumor depth from 1.01 to 2.00 mm, 1871 (31%) with a tumor depth from 2.01 to 4.00 mm, and 1487 (24%) with a tumor depth >4.00 mm; and the respective 5-year DSS rates were 63%, 76%, 75%, 60%, and 43%. Multivariable analysis confirmed a similar trend in HRs for DSS: The HR was 1.00 for a tumor depth ≤0.50 mm (reference category) and 0.64 (P <.001), 0.65 (P <.001), 0.95 (P =.57), and 1.42 (P <.001) for tumor depths of 0.51 to 1.00 mm, 1.01 to 2.00 mm, 2.01 to 4.00 mm, and >4.00 mm, respectively. This association of tumor depth with DSS persisted for N1 and N2 disease but not for N3 disease. CONCLUSIONS: Ultrathin melanoma (≤0.50 mm) was identified as a marker of poor prognosis in the setting of lymph node metastasis. These results may improve recommendations for adjuvant therapy, surveillance protocols, and risk stratification for clinical trials. Cancer 2013.

Original languageEnglish (US)
Pages (from-to)1860-1867
Number of pages8
JournalCancer
Volume119
Issue number10
DOIs
StatePublished - May 15 2013

Fingerprint

Melanoma
Lymph Nodes
Skin
Neoplasms
Neoplasm Metastasis
Survival
Lymph
Proportional Hazards Models
Registries
Epidemiology
Survival Rate
Clinical Trials

Keywords

  • biomarker
  • lymph node metastasis
  • melanoma
  • prognosis
  • tumor depth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. / Bagaria, Sanjay P.; Ray, Partha S.; Joseph, Richard W; Heckman, Michael G.; Rawal, Bhupendra; Gray, Richard J.; Pockaj, Barbara A; Wasif, Nabil.

In: Cancer, Vol. 119, No. 10, 15.05.2013, p. 1860-1867.

Research output: Contribution to journalArticle

Bagaria, Sanjay P. ; Ray, Partha S. ; Joseph, Richard W ; Heckman, Michael G. ; Rawal, Bhupendra ; Gray, Richard J. ; Pockaj, Barbara A ; Wasif, Nabil. / Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma. In: Cancer. 2013 ; Vol. 119, No. 10. pp. 1860-1867.
@article{3a0100809eb44fda836628a02e896d11,
title = "Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma",
abstract = "BACKGROUND: Lymph lymph node metastasis from melanoma ≤0.50 mm (ultrathin) is an infrequent event. However, because many newly diagnosed melanomas are ultrathin, a significant proportion of patients who present with lymph node disease have an ultrathin melanoma. The authors hypothesized that ultrathin melanomas that present with lymph node metastasis represent biologically aggressive lesions with a worse prognosis. METHODS: The Surveillance, Epidemiology, and End Results registry data were queried to identify patients with cutaneous melanoma who presented with lymph node metastasis diagnosed between 1998 and 2008. Hazard ratios (HRs) from Cox proportional hazards regression models were used to compare disease-specific survival (DSS) between various tumor depths. RESULTS: In total, 6134 patients with lymph node-positive melanoma were identified and stratified according to tumor depth, including 588 (10{\%}) with a tumor depth ≤0.50 mm, 519 (8{\%}) with a tumor depth from 0.51 to 1.00 mm, 1669 (27{\%}) with a tumor depth from 1.01 to 2.00 mm, 1871 (31{\%}) with a tumor depth from 2.01 to 4.00 mm, and 1487 (24{\%}) with a tumor depth >4.00 mm; and the respective 5-year DSS rates were 63{\%}, 76{\%}, 75{\%}, 60{\%}, and 43{\%}. Multivariable analysis confirmed a similar trend in HRs for DSS: The HR was 1.00 for a tumor depth ≤0.50 mm (reference category) and 0.64 (P <.001), 0.65 (P <.001), 0.95 (P =.57), and 1.42 (P <.001) for tumor depths of 0.51 to 1.00 mm, 1.01 to 2.00 mm, 2.01 to 4.00 mm, and >4.00 mm, respectively. This association of tumor depth with DSS persisted for N1 and N2 disease but not for N3 disease. CONCLUSIONS: Ultrathin melanoma (≤0.50 mm) was identified as a marker of poor prognosis in the setting of lymph node metastasis. These results may improve recommendations for adjuvant therapy, surveillance protocols, and risk stratification for clinical trials. Cancer 2013.",
keywords = "biomarker, lymph node metastasis, melanoma, prognosis, tumor depth",
author = "Bagaria, {Sanjay P.} and Ray, {Partha S.} and Joseph, {Richard W} and Heckman, {Michael G.} and Bhupendra Rawal and Gray, {Richard J.} and Pockaj, {Barbara A} and Nabil Wasif",
year = "2013",
month = "5",
day = "15",
doi = "10.1002/cncr.27985",
language = "English (US)",
volume = "119",
pages = "1860--1867",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Ultrathin primary is a marker for worse prognosis in lymph node-positive cutaneous melanoma

AU - Bagaria, Sanjay P.

AU - Ray, Partha S.

AU - Joseph, Richard W

AU - Heckman, Michael G.

AU - Rawal, Bhupendra

AU - Gray, Richard J.

AU - Pockaj, Barbara A

AU - Wasif, Nabil

PY - 2013/5/15

Y1 - 2013/5/15

N2 - BACKGROUND: Lymph lymph node metastasis from melanoma ≤0.50 mm (ultrathin) is an infrequent event. However, because many newly diagnosed melanomas are ultrathin, a significant proportion of patients who present with lymph node disease have an ultrathin melanoma. The authors hypothesized that ultrathin melanomas that present with lymph node metastasis represent biologically aggressive lesions with a worse prognosis. METHODS: The Surveillance, Epidemiology, and End Results registry data were queried to identify patients with cutaneous melanoma who presented with lymph node metastasis diagnosed between 1998 and 2008. Hazard ratios (HRs) from Cox proportional hazards regression models were used to compare disease-specific survival (DSS) between various tumor depths. RESULTS: In total, 6134 patients with lymph node-positive melanoma were identified and stratified according to tumor depth, including 588 (10%) with a tumor depth ≤0.50 mm, 519 (8%) with a tumor depth from 0.51 to 1.00 mm, 1669 (27%) with a tumor depth from 1.01 to 2.00 mm, 1871 (31%) with a tumor depth from 2.01 to 4.00 mm, and 1487 (24%) with a tumor depth >4.00 mm; and the respective 5-year DSS rates were 63%, 76%, 75%, 60%, and 43%. Multivariable analysis confirmed a similar trend in HRs for DSS: The HR was 1.00 for a tumor depth ≤0.50 mm (reference category) and 0.64 (P <.001), 0.65 (P <.001), 0.95 (P =.57), and 1.42 (P <.001) for tumor depths of 0.51 to 1.00 mm, 1.01 to 2.00 mm, 2.01 to 4.00 mm, and >4.00 mm, respectively. This association of tumor depth with DSS persisted for N1 and N2 disease but not for N3 disease. CONCLUSIONS: Ultrathin melanoma (≤0.50 mm) was identified as a marker of poor prognosis in the setting of lymph node metastasis. These results may improve recommendations for adjuvant therapy, surveillance protocols, and risk stratification for clinical trials. Cancer 2013.

AB - BACKGROUND: Lymph lymph node metastasis from melanoma ≤0.50 mm (ultrathin) is an infrequent event. However, because many newly diagnosed melanomas are ultrathin, a significant proportion of patients who present with lymph node disease have an ultrathin melanoma. The authors hypothesized that ultrathin melanomas that present with lymph node metastasis represent biologically aggressive lesions with a worse prognosis. METHODS: The Surveillance, Epidemiology, and End Results registry data were queried to identify patients with cutaneous melanoma who presented with lymph node metastasis diagnosed between 1998 and 2008. Hazard ratios (HRs) from Cox proportional hazards regression models were used to compare disease-specific survival (DSS) between various tumor depths. RESULTS: In total, 6134 patients with lymph node-positive melanoma were identified and stratified according to tumor depth, including 588 (10%) with a tumor depth ≤0.50 mm, 519 (8%) with a tumor depth from 0.51 to 1.00 mm, 1669 (27%) with a tumor depth from 1.01 to 2.00 mm, 1871 (31%) with a tumor depth from 2.01 to 4.00 mm, and 1487 (24%) with a tumor depth >4.00 mm; and the respective 5-year DSS rates were 63%, 76%, 75%, 60%, and 43%. Multivariable analysis confirmed a similar trend in HRs for DSS: The HR was 1.00 for a tumor depth ≤0.50 mm (reference category) and 0.64 (P <.001), 0.65 (P <.001), 0.95 (P =.57), and 1.42 (P <.001) for tumor depths of 0.51 to 1.00 mm, 1.01 to 2.00 mm, 2.01 to 4.00 mm, and >4.00 mm, respectively. This association of tumor depth with DSS persisted for N1 and N2 disease but not for N3 disease. CONCLUSIONS: Ultrathin melanoma (≤0.50 mm) was identified as a marker of poor prognosis in the setting of lymph node metastasis. These results may improve recommendations for adjuvant therapy, surveillance protocols, and risk stratification for clinical trials. Cancer 2013.

KW - biomarker

KW - lymph node metastasis

KW - melanoma

KW - prognosis

KW - tumor depth

UR - http://www.scopus.com/inward/record.url?scp=84877577038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877577038&partnerID=8YFLogxK

U2 - 10.1002/cncr.27985

DO - 10.1002/cncr.27985

M3 - Article

VL - 119

SP - 1860

EP - 1867

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -